ASHE NEIL sold $9.7M of AYI

ASHE NEIL (President & CEO) sold 30,247 shares of ACUITY INC. (DE) (AYI) at an average of $319.25 ($314.53–$327.30, $9.66M total) across 15 trades over 2026-10-28 to 2026-10-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ASHE NEIL
Published Oct 30, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AYI
Bearish
medium confidence
Mentioned
$AYI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AYIBearishLow
01

Why it matters

The insider sale may trigger short‑term selling pressure but is likely already priced in due to the pre‑arranged nature of the 10b5‑1 plan.

02

Market read

Primary disclosure of a sizable insider sell; modest relevance for traders monitoring AYI.

03

What to watch

The 10b5‑1 plan indicates the sale was scheduled in advance, reducing the informational content of the transaction.

Relevance 5/10Novelty 7/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions. Acuity Inc. (AYI) is a U.S.-listed medical‑device company.

Company-level read

Ticker impact

$AYIBearishMedium confidence
Context

CEO Ashe Neil sold 30,247 shares of Acuity Inc. for $9.66 M via a 10b5‑1 plan, reducing his stake to 78,075 shares.

Expected impact

likely modest downward pressure as the market prices in the insider sell

Evidence & confidence

A $9.6 M sale by the CEO is material for a mid‑cap stock and may be interpreted as reduced confidence, prompting short‑term selling.

Market effects

Minimal impact on the broader medical‑device sector; the sale is company‑specific.

U.S. market only; no regional ripple effect.

Low; the filing is a routine insider transaction.

Counterpoint

The sale could be a pre‑planned liquidity event unrelated to company fundamentals, so price impact may be limited.

Key entities

  • Acuity Inc.

    Medical‑device manufacturer listed on NYSE under ticker AYI.

  • Ashe Neil

    President & CEO of Acuity Inc., reporting the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AYIHighAI 9/10

Acuity to acquire Parameter Technologies for $675 million

Acuity Inc. (AYI) agreed to acquire Parameter Technologies for $675M. Parameter, which provides data center monitoring solutions, expects $100M in 2027 sales with 40% EBITDA margins. Acuity will fund the deal with $500M in debt and cash, aiming to close in Q2 2027. The acquisition is expected to boost Acuity's earnings per share.